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Abstract
The challenge in controlling stochastic systems in which random events can set the
system on catastrophic trajectories is to develop a robust ability to respond to such
events without significantly compromising the optimality of the baseline control policy.
Drug resistance can emerge from random and variable mutations in targeted cell popula-
tions; in the absence of an appropriate dosing policy, emergent resistant subpopulations
can proliferate and lead to treatment failure. Dynamic feedback dosage control holds
promise in combatting this phenomenon, but cell population evolutionary dynamics are
complex, stochastic, and often high-dimensional, posing significant challenges to system
control. This paper presents CelluDose, a deep reinforcement learning closed-loop dy-
namic control prototype for automated precision drug dosing targeting stochastic and
heterogeneous cell proliferation. Developing optimal dosing schedules for preventing
therapy-induced drug resistance involves a tradeoff between the effective suppression
of emergent resistant cell subpopulations and the use of conservative dosages and a
preference for first-line drugs. CelluDose is trained on model simulations of cell popu-
lation evolutionary dynamics that combine a system of stochastic differential equations
and the additional occurrence of random perturbing events. Both the single-drug and
combination therapy policies obtained in training exhibit a 100% success rate at sup-
pressing simulated heterogeneous harmful cell growth and responding to diverse system
fluctuations and perturbations within the alloted time and using conservative dosing.
The policies obtained were found to be highly robust to model parameter changes and
fluctuations not introduced during training.
1 Introduction
The development of drug resistance in response to therapy is a major cause of treatment
failure worldwide across a variety of diseases, patient populations, and administered drugs.
Resistance to a drug can be present prior to treatment or it can emerge during treat-
ment [1–3] through a variety of mechanisms. Drug resistance evolves dynamically and often
non-uniformly: intercellular variability can lead to faster adaptation to environmental pres-
sures [4] and thus promote the rise of resistant subpopulations in a previously-susceptible
population of cells. Tumor heterogeneity is now understood to be a major contributor to
drug resistance in cancer [1, 5–7], and variability in resistance among bacterial cell pop-
ulations has been tied to treatment failure [8, 9]. In bacterial evolution experiments, the
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emergence of multiple antibiotic-resistant cell lines has been observed [10, 11]. Such clonal
diversity, even in a majority-susceptible cell population, can be the harbinger of drug resis-
tance that ultimately leads to treatment failure: improper treatments can exert a selective
evolutionary pressure that leads to the elimination of susceptible cell populations but leaves
more resistant cells largely unaffected and able to proliferate due to reduced competition
with susceptible cells [12].
The emergence and potential rise to dominance of resistant strains are stochastic pro-
cesses driven by the dynamic and complex interaction between the influences and interplay
of natural selection, demographic stochasticity, and environmental fluctuations. A predic-
tive understanding of the likely evolutionary trajectories toward drug resistance is key to
developing treatments that can effectively target and suppress resistant cell populations, but
a fully predictive understanding of such processes remains a challenge. Control of evolution,
however, does not in principle require full predictability or determinism in evolution. In a
closed-loop setting, system feedback can mitigate the reliance on precise trajectory knowl-
edge, so long as this feedback can be obtained at reasonable time intervals, the uncertainty
and stochasticity can be approximated in an informed manner, and the controller is suffi-
ciently robust to changes in system behavior and parameter fluctuations. In heterogeneous
cell environments prone to resistance evolution, the development of such a control policy
must balance the need for properly and efficiently targeting all cell types that may either
exist at the onset of treatment or that may spontaneously emerge during therapy, while
maintaining sufficiently low dosing for toxicity minimization.
The focus of this work is on the development of a closed-loop dynamic control prototype,
CelluDose, for precision dosing that adaptively targets harmful cell populations of variable
drug susceptibility and resistance levels based on discrete-time feedback on the targeted
cell population structure. The time evolution of such systems is influenced by the potential
presence, random emergence, and stochastic growth of multiple cell subpopulations, where
demographic stochasticity arises from random processes on the single-cell level. Inappro-
priate dosing can lead to the proliferation of resistant cell populations, but this interplay is
subject to significant levels of stochasticity that must be accounted for in the design of the
control algorithm. The target goal of CelluDose is to combat the emergence of drug resis-
tance during treatment by sensitively adjusting dosage and/or switching the administered
drug in response to observed feedback on changes in the cell population structure while
employing minimal overall drug dosage for toxicity reduction.
Significant and variable stochasticity, nonlinearity in the dynamics, and the potentially
high-dimensional space of cell types pose significant challenges to the application of classical
control methods to such systems. This extends beyond the scenarios considered in this pa-
per: work on more complex disease progression and drug response models with anticipated
higher predictive power has been on the rise in recent years, such as in systems pharmacol-
ogy [13, 14], which brings systems biology approaches into integrative quantitative modeling
in the drug discovery process. The expectation is that these increases in model complexity
will result in more realistic descriptions of the dynamics that would offer significantly im-
proved predictive power. However, as model complexity increases, the problem of disease
progression control by way of model-informed precision dosing [15–19] becomes increasingly
less tractable, necessitating a tradeoff between the ability to develop a controller for the
system and the predictive accuracy of the system model [20].
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A shift away from model-based control methods toward approaches that do not or only
partly rely on model details will permit greater freedom in model selection and obviate
the need for simplifications that may reduce predictability. The application of model-free
reinforcement learning methods to continuous control tasks has seen significant advances
in recent years1 and holds promise for the control of systems for which mathematical opti-
mization and control may be intractable, with potential applications in diverse fields that
include robotics, mathematical finance, and healthcare. However, for reinforcement learning
to become a standard tool in control engineering and related fields more work is needed in
the successful application of continuous reinforcement learning control to highly stochastic
and realistic environments.
CelluDose combines a model-free deep reinforcement learning algorithm with model
information in developing an adaptive dosing control policy for the elimination of harmful
cell populations with heterogeneous drug responses and random yet significant demographic
stochastic changes. Beyond presenting this implementation, the aims of this work are
additionally to (1) motivate the use of model-free reinforcement learning control in the
development of next-generation precision dosing controllers by demonstrating that a reliable
and highly responsive dynamic control policy can be obtained for a complex and stochastic
biological system that is intractable with traditional control methods, and (2) showcase how
model knowledge may be capitalized on in such a scheme while still benefitting from the
flexibility of its model-free learning approach.
2 Background
2.1 Reinforcement learning for continuous control
The aim of a therapeutic agent targeting harmful cell populations is to produce an effect that
leads to the elimination of the harmful cell population while minimizing toxicity by avoiding
the use of high doses. Given the possibility of emergence of high-resistance cell populations,
this task involves a potentially complex tradeoff between acceptably low dosing levels, the
need to effectively eliminate the targeted cell populations, and a preference for shorter
treatment times to reduce patient morbidity and – in infectious diseases – the possibility of
further contagion. As a result, the dosing problem can be cast in somewhat different ways
that depend on the particular disease conditions and prevailing treatment preferences. For
the purposes of this work, a successful treatment is defined as one in which all targeted
harmful cell subpopulations were eliminated by some maximal acceptable treatment time.
Within this measure of success optimality is defined as lowest expected cumulative dosing
over the course of the treatment. A treatment course is designated as a failure if any
targeted cells remain after the maximal treatment time has been reached, with the extent
of failure dependent on the number of remaining cells.
Model-free reinforcement learning (RL) approaches aim to learn an optimal decision-
making policy through an iterative process in which the policy is gradually improved by
sequential tuning of parameters either of the policy itself or of a value (e.g. the action-
value function) indicative of the policy’s optimality. The data on which learning is done is
supplied in the form of transitions from a previous state s of the environment to the next
1See, e.g., [21, 22] for recent surveys.
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state s′ that occurs probabilistically (in stochastic environments) when a certain action a
is chosen. Each such transition is assigned a reward r, and reward maximization drives the
optimization of the policy. Learning can be done on a step-by-step basis or episodically,
where a single episode consists of multiple steps of transitions. In the case of the dosing
problem considered here, an episode is a single-patient full course of therapy. It ends when
either the maximal time has been reached or all cells have been eliminated, whichever comes
first. Episodes are thus finite but can be long, with drugs administered at discrete time
steps over a continuous range of dosages. At each time interval, a decision is made on which
drugs at what doses should be administered based on observations of the current state of
the disease, defined as the concentrations of the targeted cell types. However, only at the
end of each episode does it become clear whether or not the sequence of therapeutic actions
was in fact successful. This credit assignment problem [23] frequently plagues episodic tasks
and will be addressed in Section 3.2.
The optimal policy for this decision-making process needs to provide next-time-step
dosing guidelines under the optimality guidelines described above and based on poten-
tial stochastic evolutionary scenarios described by the model in Section 3.1. This system
is continuous in its state space (cell population composition), involves time-varying and
potentially high stochasticity, can be high-dimensional due to the large number of possibly-
occurring mutant cell types, and involves one or multiple controls (drugs) that if adminis-
tered intravenously (the scenario of interest here) can in principle take a continuous range
of values. For reasons of mechanical operability and medical explainability, a deterministic
dosing policy is needed in this case.
Deep deterministic policy gradient (DDPG) [24] is an off-policy actor-critic deterministic
policy deep reinforcement learning algorithm suitable for continuous and high-dimensional
observation and action spaces. Building on the deterministic policy gradient algorithm [25],
DDPG employs neural network function approximation through the incorporation of two
improvements used in Deep Q Networks [26, 27] for increasing learning stability: the use
of target networks and a replay buffer from which mini-batches of (s, a, s′, r) transitions
are sampled during training. We note that while the action space in the dosing problem
is typically low-dimensional (only a few drugs are typically considered for treatment of a
particular disease), the observation space (number of cell types) can be quite large, especially
if finer observations are available on cellular heterogeneity (finer differentiations in dose
responses). For these reasons, the dosing control scheme described here employs the DDPG
algorithm.
2.2 Model-informed treatment planning with reinforcement learning
The benefit of a mechanistic model-informed approach to treatment planning is the ability to
explore therapeutic decisions prior to the start of or as an accompaniment to clinical trials,
which can then be used to inform clinical trials. The simulation-based use of RL here thus
differs from work that employs reinforcement learning for making decisions based on patient
data and clinical outcomes, where exploration of treatment parameter space is constrained
by data available from previously-attempted treatments. When this data becomes available
during and after clinical trials, these approaches and the approach presented here could be
used in a complementary manner to inform and improve individualized treatments.
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The use of RL for mechanistic model control in treatment planning is less common than
data-driven approaches. We note below a few applications of interest. Q-learning [28], a
discrete state and action space RL algorithm, was employed in [29] for closed-loop control
of propofol anesthesia and in [30] for control of cancer chemotherapy based on an ordinary
differential equations (ODE)-based deterministic model of tumor growth. In [31] a natural
actor-critic algorithm [32] was employed for cancer chemotherapy control of a similar ODE-
based model, with a binary action space (drug or no drug). Tumors were taken to be
uniform and resistance to treatment was not considered as part of the models used in [30]
and [31]. In [33] a DDPG-based algorithm was applied to an agent-based model of sepsis
progression for obtaining an adaptive cytokine therapy policy.
Interest in adaptive control of therapy that takes resistance evolution into account has
been on the rise in recent years (see, e.g., [34, 35]) but these efforts have been restricted
to simple models that are typically low dimensional and/or deterministic. The approach
presented here provides a mechanism for determining and automating dosing in a respon-
sive and robust way that can be generalized to arbitrarily heterogeneous cell populations
exhibiting complex and realistic dynamics. Both single-drug and combination therapy con-
trol policies are developed in this context, and observations on population composition are
supplied at discrete time intervals, as would be expected in a laboratory or clinical scenario.
By extension, this work seeks to motivate efforts in the high-resolution tracking of cell-level
drug resistance progression within an individual patient. From a control engineering per-
spective, the incorporation of model information into model-free learning presented here
may be usefully transported and adapted to the control of other stochastic systems with
an equations-based description for improved RL learning stability and convergence. For
reinforcement learning insights, a detailed analysis is included of policy features that were
observed in training.
2.3 Implementation and workflow
Training and implementation rely on three key components: model and simulation develop-
ment, selection of the subset of drugs of interest, knowledge of the range of likely resistance
levels that have been recorded in response to these drugs, and access to diagnostics that
can provide temporal data on cell population structure. In this paper, all data supplied in
training is simulated; we describe below how such data may be obtained for future proof-
of-concept validation.
For demonstrative purposes and facility of near-future validation, the focus of this work
is on drug resistance in evolving bacterial populations subjected to growth-inhibiting antibi-
otic drugs. We note that evolutionary models of cell population dynamics are widely used to
understand and model cancer progression and the development of resistance to chemother-
apy treatment, and that another promising application area for a CelluDose-based platform
is in cancer chemotherapy control.
Future clinical implementation of a CelluDose-based controller could be as an integrated
system with the ability to track and supply the trained control model with sensitive mea-
surements of the presence of small populations of cells and equipped with an automated
intravenous infusion mechanism. This implementation would be particularly useful in inten-
sive care units (ICUs), where the development of resistance to therapy is a major concern,
5
therapy is performed in the controlled environment of the clinic, and substantial genetic
diversity in bacterial strains has been observed [37]. Alternatively, in longer-term therapies,
it could be implemented as a decision support tool providing informed dosing recommen-
dations to clinicians. In both cases, observations at the chosen fixed time intervals for
which training was done would be supplied in the form of the respective targeted cell type
concentrations, where a distinct cell type is (phenotypically) defined by non-negligible dif-
ferences in the dose response across the possible ranges of dosages that are permitted for
administration.
2.3.1 Modeling and simulation
Although training implements a model-free reinforcement learning algorithm, model knowl-
edge is used in two ways: to provide the training data (as simulation data) and for algorithm
design via feature engineering and reward assignment. This feature engineering is made pos-
sible by trajectory estimation from the equations-based component of the growth-mutation
model implemented here. This model combines (1) a stochastic differential equations-based
system for approximating the growth of existing cell subpopulations with (2) external ran-
dom events that perturb this system by creating new subpopulations of resistant cells.
These events, which increase the effective dimensionality and alter the composition of the
system at random points in time, can be thought of as either de novo resistant mutations
that occur during therapy or as the above-detection-threshold rise of mutant populations.
The resulting system exhibits variable and substantial levels of stochasticity that can sig-
nificantly alter its trajectory and potentially lead to treatment failure (see Fig. 1). Since,
as shown in Section 4, the learned policies are highly robust to changes in the key mutation
parameters, detailed knowledge of mutation rates is not an essential training parameter.
Stochasticity can arise from both demographic and environmental fluctuations. The
focus here is on demographic stochasticity arising from single-cell variability in birth, death,
and mutation processes. For simplicity, spatial homogeneity and a constant environment
(other than changes in drug administration) will be assumed here. To obtain a quantifiable
estimate of demographic stochasticity, a stochastic physics approach was employed here
(Appendix A) in deriving the system of stochastic differential equations describing the
heterogeneous cell population time evolution. This permits an informed estimate of the
extent of demographic noise from individual cells’ probabilistic behavior and a subsequent
quantification of an important contribution to risk in disease progression.
The universal parameters that enter the model are the drugs that may be used with pref-
erence information (e.g. which ones are first-line vs. last-line), the appropriate discrete time
intervals in which observations become available and dosing can be altered, and the likely
spectrum of dose responses. In laboratory evolution experiments [38] this spectrum (e.g.
see Fig. 2) can be obtained by allowing the bacteria to naturally evolve under different drug
levels and identifying subsequent cell lines accompanied by a characterization of their dose
responses through parameter fitting of their growth curves at different drug concentrations.
We note that it is not in general necessary to identify all possible and potential mutations
prior to training. In particular, knowledge of all possible genetic changes is not in principle
necessary: it suffices to characterize the expected relevant diversity in drug response2. The
2Such studies, however, are frequently accompanied by genotype analysis.
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idea is to provide enough training data for the model so that new variants are unlikely to
exhibit dose responses considerably different from all those already identified. During an
experimental run of the trained RL model, when a newly-emergent cell type subpopulation
is detected it can thus be binned without significant loss of accuracy into the state-space
dimension (Section 3.2) of a previously-identified variant.
2.3.2 Observations and diagnostics
Early, fast, and high-resolution detection of heterogeneity in drug response is crucial for
identifying resistant cell subpopulations before such populations spread [8, 39, 40]. Re-
sistance detection may be done through phenotype-based drug susceptibility testing or by
capitalizing on advances in genomic sequencing in combination with predictions of resis-
tance from genotype [11, 41]. A key aspect is the requisite ability to effectively detect low
concentrations of resistant cells in an otherwise suseptible population. Single-cell analysis
is showing mounting promise in this regard and is being used to resolve heterogeneity in tu-
mors [42] and in bacterial populations [43, 44]. Direct phenotype-based detection of small
resistant bacterial subpopulations in proportions as low as 10−6 of the total population
was performed in [45]. For genotype detection, single-cell sequencing [46] can be combined
with predictions of resistance from genotype for high-resolution detection of a population’s
resistance profile.
These advances could be applied to near-future laboratory validation of an in vitro Cel-
luDose controller via combination with software implementation into an automated liquid
handling system in bacterial evolution experiments. Greater automation, efficiency, and
standardization are nonetheless needed for these technologies to be routinely employed as
part of a clinical controller apparatus, and, in part, the intention of this work is to motivate
efforts in the clinical development and use of single-cell analysis for resistance profiling by
demonstrating its potential utility for automated disease control.
3 Methods
3.1 Stochastic modeling and simulation of cell population evolution
The evolutionary fate of an individual cell during any given time interval depends on the
timing of its cell cycle and its interaction with and response to its environment. The
model of evolutionary dynamics employed here depends on three processes: cell birth, cell
death, and inheritable changes in cell characteristics that lead to observable changes in
growth under inhibition by an antibiotic. We consider here drugs that suppress cell growth
by inhibiting processes essential for cell division by binding to relevant targets and thus
leading to reduced cell birth rates. The dose-response relationship can be described by a
Hill-type relationship [47, 48]. Here a modified Hill-type equation will be employed that
includes the potential use of multiple drugs with concentrations given by I = (I1, ..., Im).
The growth rate gi of a particular cell type i as a function of the drug concentrations to
which cells are exposed is thus taken to be
gi (I) = βi (I)− δi = βi,0
1 +
∑
α (Iα/ρi,α)
− δi (1)
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where βi is the rate of cell birth, βi,0 is its drug-free birth rate, δi is the rate of cell death, and
ρi,α describes the extent of resistance of cell type i to drug α. For simplicity, since drugs are
assumed here to affect only birth rates, changes that confer resistance are assumed to affect
only βi (I) rather than δi. Resources for cell growth are assumed to be limited, with the
environmental carrying capacity denoted by K, indicating the total bacterial cell population
size beyond which no further population increases take place due to resource saturation.
Evolution is an inherently stochastic process that depends on processes, as noted above,
that individual cells undergo. However, individual (agent)-based simulations are generally
very costly for larger numbers of cells and, moreover, obscure insight into any approximate
deterministic information about the system. At very high population levels (that can be
treated as effectively infinite) a deterministic description of system dynamics is appropri-
ate. In the dynamic growth scenario considered here, large size discrepancies can exist at
any time between the various concurrent cell populations, and a single population can de-
cay or proliferate as the simulation progresses. The extent of demographic stochasticity in
such systems will thus change in the course of evolution. For efficient modeling at higher
population levels it is imperative to use a simulation model whose runtime does not scale
with population size, but for accurate modeling a proper estimate of stochasticity must be
included. This is done here by applying methods from stochastic physics [49–51] to derive
a diffusion approximation of a master equation describing the continuous-time evolution of
the probability distribution of the population being in some state (n1, n2, ..., nd), where ni
are the (discrete) subpopulation levels for the different cell types. This approximation relies
on the assumption that the environmental carrying capacity is large compared to individ-
ual subpopulation levels ni and results in the evolution of the system being described by a
system of stochastic differential equations (SDEs) governing the time evolution of the sub-
population levels of the different cell types given by the continuous variables x = (x1, ..., xd),
where d is the number of distinct phenotypes that may arise. We only consider phenotypes
whose growth rate gi (I) at nonzero drug concentrations is higher than the baseline sus-
ceptible phenotype (wildtype) due to the negative evolutionary selection experienced by
phenotypes with lower growth rates. The system evolves according to (Appendix A)
dxi(t)
dt
= (βi (I)− δi)xi(t)
(
1−
∑d
j=1 xj(t)
K
)
+
√√√√(βi (I) + δi)xi(t)(1− ∑dj=1 xj(t)
K
)
Wi(t),
(2)
where i = 1, .., d and the white noise Wi(t) satisfies{
〈Wi(t)〉 = 0
〈Wi(t)Wi(t′)〉 = δ(t− t′).
From a control standpoint, the advantage of using SDEs over an agent-based model
is that we can capitalize on the equations-based description for trajectory estimation and
use that information in feature engineering and reward assignment below. Note that the
stochastic noise in these equations is not put in ad hoc but instead emerges naturally from
population demographic randomness that arises from demographic processes on the level
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of single cells3. For more realistic dynamics at very low cell levels, when the level of a
subpopulation falls below 10 cells, the number of cells is discretized by a random choice
(equal probability) to round up or down to the nearest integer cells after each stochastic
simulation step; when cell numbers fall below 1 the subpopulation level is set to zero.
A few comments are due on the large-K approximation above (see Appendix A for de-
tails) in the context of the work here. In general, as xj → K, this approximation ceases to
provide a good description of the fluctuations in the system. In that regime, the large-K
approximation leads to deterministic dynamics and neglects the effect of population fluctua-
tions near carrying capacity, which are expected in biological systems. This is not a concern
in the scenario considered here: since K is assumed here to be large, as xj approaches K
its dynamics become effectively deterministic and well-described by the logistic drift term
alone; moreover, the treatment goal is to reduce the cell populations rather than maintain
some distribution near carrying capacity, so that after the onset of treatment populations
should spend little time in the vicinity of the resource capacity. As a result, any fluctuations
at that point will have negligible effect on the progression of treatment. As the population
decreases it moves farther away from the resource capacity and into the regime in which
the diffusion term is a valid approximation of stochasticity, whose contribution to the dy-
namics also increases at lower population sizes due to the dependence on xi. The logistic
deterministic dependence, however, is relevant for modeling accuracy at the initial stages
of treatment (where it can affect the growth rate) as well as for training: a finite resource
capacity introduces into training the issue of low growth despite population proliferation
(and hence treatment failure). This needed to be addressed with a particular reward as-
signment scheme, discussed in Section 3.2, and was done for potential future generalization
to scenarios where the population levels may stay for longer closer to the carrying capacity
due to treatment constraints. Lastly, setting a carrying capacity motivated a non-arbitrary
scale in the problem for feature rescaling (Appendix B).
For clarity, in this paper the term decision time step will be used to refer to the length
of time between each dosing decision and thus defines the RL time step, whereas SDE
simulation step will be used to refer to a stochastic simulation step. A single decision time
step thus contains a large number of SDE simulation steps. The evolution of Eq. (2) was
simulated via the Euler-Maruyama method with a step size of 0.01 over the 4-hour decision
time step (unless all populations drop to zero before the end of the decision time step is
reached).
Mutations are modeled here as random discrete external events that perturb the system
of Eq. 2 by injecting new population members into a particular subpopulation xi. For
simplicity, resistance is assumed to be acquired as a one-step process by mutation from
wildtype; while resistance has been observed to increase with the accumulation of mutations,
single mutations can suffice to confer resistance [52, 53]. During training (Section 3.2) there
is a Pepis,mut probability that any mutations will occur during an episode, so that mutations
are precluded from occurring in most episodes. This is done in order to permit the policy
to identify an optimal baseline (no mutation) dosing schedule.
When mutations are allowed, they are permitted to occur at any time step up until
24 hours before the maximal time allowed for treatment, where the maximal time is set at
3Other sources of noise due to environmental factors would in general be expected to exist as well and
can be included in the model. Here we restrict to demographic stochasticity.
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substantially longer than the time necessary to eliminate the cell population if no mutations
were to occur. This restriction is set in place as any mutations at the very end of treatment
will always necessitate an extension past the maximal time, which is already built in by
setting the maximal time at longer than the necessary time. Within these bounds mutations
may occur to any (or all) of a potential set of prespecified phenotypes at any decision time
step with some fixed small probability Pstep,mut. When a resistant population randomly
emerges in this manner, its population size is assigned through a combination of random
number generation and size estimation based on the expected deterministic increase in the
baseline (bl) population level if it were the only present cell type:
Nmut,expected = dζ × xble
βbl(I)τ
1 + xblK
(
eβbl(I)τ − 1)e, (3)
where τ is the decision time interval and ζ is generated randomly (in steps of 5×10−6) from
a uniform distribution between 5× 10−6 and 5× 10−5, in keeping with typical approximate
observed rates of occurrence of resistant mutant cells in bacterial populations [8]). The
rationale behind Eq. (3) is that larger populations will naturally give rise to more mutant
cells. Rounding up is done both due to the typically low cell numbers (individual statistics
modeling, as noted above), and in order to partially offset the low probability of mutation
occurrence. If a mutation occurs to a particular phenotype, then Nmut,expected is added
to that phenotype’s subpopulation and, as an approximation, removed from the baseline
phenotype’s subpopulation, as fewer cells are now available for its further growth. These
population adjustments are done prior to simulating the stochastic evolution of the system
via Eq. (2) for that decision time step.
Fig. 1 shows several model simulations for a constant low dose case that is above the
susceptibility level of the initially-dominant phenotype but below that of three potential
variants. All dose responses are shown in their respective colors in Fig. 2; the (simulated)
parameters used are not specific to any particular organism or drug but fall within common
concentration and growth rate ranges.
3.2 Learning an adaptive dosing policy
As discussed in Section 2.1, DDPG [24] was employed for training. Below we describe
the state and action spaces and reward assignment. The neural network architecture and
hyperparameter choices for the neural network and RL components are given in Appendix B.
In training, the maximal time for an episode was set at 7 days, with dosing decision
steps of 4 hours. Although time scales for observations will be technology-dependent and
possibly longer, this time interval was put in place in order to demonstrate the ability of the
algorithm to handle episodes with many decision time steps, and hence a near-continuous
dose adjustment, and produce a robust control policy able to adaptively and responsively
adjust to changes in the cell population composition. To put in clinical context the maximal
treatment time chosen, we note that a 2000 study [54] found that in a studied patient
cohort typical ICU antibiotic courses lasted for 4-20 days, with an average length of 10
days; after 7 days of a standard antibiotic course 35% of patients in the study were found
to have developed antibiotic resistance (new resistant patterns in the original pathogen)
or superinfections (newly-detected pathogenic organisms not originally present). Shorter
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Figure 1: Sample evolutionary simulations for four pheno-
types with dose-response curves shown in Fig. 2. The hori-
zontal and vertical axes represent, respectively, time (hours)
and cell concentration. The initial state in any simulation
was a population comprised entirely of the (most suscepti-
ble) baseline phenotype with a population of between 106-
107 (random initialization), but mutations were allowed from
the first time step and could occur at any subsequent time
step (4 hour intervals). The carrying capacity K was set at
1.2×107. The dosage was set at a constant 0.5 µg/mL for the
duration of treatment, which is higher than ρ for the black
phenotype but lower than ρ for the blue, red, green phe-
notypes. Even when a phenotype is sufficiently strong to
survive the dosing, random demographic fluctuations may
eliminate its nascent population, as shown in several of the
plots. Even when no mutations occur, variability in ini-
tial population as well as demographic randomness can lead
to significantly different extinction times for the susceptible
phenotype. Populations falling below 1 cell are set to zero;
for plotting purposes, due to the log scale this is shown as
having a population of just below 1 cell (0.98).
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Figure 2: Dose-response curves
for four sample (simulated) phe-
notypes, shown as growth rate as
a function of drug concentration.
The phenotype shown in black has
the highest growth rate at zero
drug inhibition. It is taken to be
the baseline phenotype dominating
the population at the onset of drug
administration in the simulations
(e.g. Fig. 1) that are used as the
RL training data. The death rate
was set at δ = 0.2 h−1 for all phe-
notypes.
treatment times (3 days) in that study correlated with a lower rate of antibiotic resistance
(15% at 7 days). Stopping antibiotic treatment prematurely, however, runs the risk of
failing to eliminate the pathogenic bacteria, suggesting that continuous monitoring and
proper dose adjustments – as recommended here – are essential in combatting treatment
failure in severe infections.
All code (simulation and RL) was written in Python, with the use of PyTorch [55] for
the deep learning components.
3.2.1 State space: model-informed feature engineering
At each decision time step an observation of the current composition of the cell population,
i.e. types and respective concentrations x = (x1, .., xd) is made. Cell types that are known
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to potentially arise but are presently unobserved are assigned xi = 0. As a result of model
knowledge in the form of the SDE system (Eq. 2), however, additional feature combinations
of x can be used to supplement and improve learning. In particular, the current growth
rate of the total cell population is highly indicative of drug effectiveness, but it is typically
difficult to measure and necessitates taking multiple observations over some fixed time
interval (e.g. 1 hour) prior to the end of a decision time step. Instead, the instantaneous
growth rate can be calculated as
gall(t) =
∑
i x˙i(t)∑
xi(t)
(4)
and approximated directly from observed features, xt, at time t by noting that in the
deterministic limit the numerator is simply given by
∑
i
x˙i(t) =
(
1−
∑
i xi
K
)
×
∑
i
gi (I)xi(t) (5)
where gi is fixed and known (Eqn. 1) during any decision time step. Hence gall is a function
exclusively of the action taken (doses chosen) and observations of cell concentrations xt.
Use of this feature combination, which would not be known in a blackbox simulation,
was found to be instrumental in shaping the reward signal at non-terminal time steps and in
leading to optimal policy learning, suggesting that such incorporation of information could
in general assist in driving policy convergence when model knowledge is available but a
model-free approach is preferred due to the complexity of the dynamics.
3.2.2 Action space
Training was performed with both a single drug It and two drugs
(
Iαt , I
β
t
)
under the same
training hyperparameters (with the exception of drug preference). Drugs were set to take a
continuous range of values from zero up to some maximal value Imax, and the action of drugs
on the cell populations is expressed through the dose-response as in Eq. (1) and the SDE
system of Eq. (2). This maximal value was used for reward scaling as shown in Section 3.2.3
rather than for placing a hard limit on the amount of drug allowed to be administered. It
was set for both drugs at 8 times the highest ρ value in the set {ρi, α} for all drugs α. This
very high value was chosen in order to allow enough initial dosing climb during training; in
practice, conservative dosing was implemented through the reward assignment alone.
3.2.3 Reward assignment
While the state space includes information on separate cell subpopulations, the terminal
(end-of-episode) reward is assigned based on only the total cell population. As noted above,
a successful episode concludes in the elimination of the targeted cell population by the
maximal allowed treatment time Tmax. In training, different drugs are assigned preference
through penalty weights wα, so that use of a last-line drug will incur a higher penalty than
that of a first-line drug, α = 1. To penalize for higher cumulative drug dosages, the reward
12
at the end of a successful episode is assigned as
rsuccess = cend,success
1− ∑mα
(
wα
w1
)∑Tmax/τ
n=1 Iα,n
c1ImaxTmax/τ
 , (6)
where Iα,n is the dosage of drug α administered at the nth decision time step, c1, cend,success >
0 are constants, and τ is the length of each decision time step. When the episode fails (the
cell population is above zero by Tmax) a negative reward is assigned with an additional
penalty that increases with a higher ratio of remaining cell concentrations to the initial cell
population in order to guide learning:
rfailure = −cend,fail
[
1 + log
(
1 +
∑
i xi (Tmax)∑
i xi (0)
)]
, (7)
where cend,fail > 0. Since the episodes can be long, in order to address the credit assignment
problem [23] a guiding signal was added at each time step in the form of potential-based
reward shaping [56]. Policy optimality was proved to be invariant under this type of reward
signal, and it can thus provide a crucial learning signal in episodic tasks. It is given by
rshape(st, a, st+τ ) = γΦ(st+τ )− Φ(st), (8)
where γ is the RL discount factor, Φ : S → R is the potential function, and S is the state
space. Since the drugs are assumed here to affect cell mechanisms responsible for cell birth,
population growth provides a direct indicator of the efficacy of the drug. The potential
function was therefore set here to
Φ = −cΦ gall
gmax
,
where cΦ > 0, gall is given by Eq. 4, and gmax is the zero-drug full-population deterministic
growth rate at t = 0 (see also Eq. 5):
gmax =
(
1−
∑
i xi(t = 0)
K
) ∑d
i xi(t = 0)gi(Iα = 0, ∀α)∑d
i xi(t = 0)
. (9)
Although incentives for low dosing were built into the terminal reward (Eq. 6), for guiding
training toward low dosing it was necessary to provide some incentive for low dosing at
each decision time step. The step reward was therefore assigned as the sum of the shaping
reward and a dosage penalty:
rstep = rshape −Θ
(∑
i
xi
)
m∑
α
wα (Iα/Imax)
2 (10)
where ηα is the specific penalty for each drug, and Θ (
∑
i xi) is a binary-valued function
explained below. For a previous implementation of step-wise action penalties with potential-
based reward shaping see [33].
An issue peculiar to the problem of a population growing under limited resources is that
if insufficient dosing is applied and the population subsequently quickly grows and reaches
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its carrying capacity, very little change in growth (or population) will occur yet the state
of infection will be at its maximal worst state. However, the shaping reward (8) – which is
based on changes from one decision time step to the next – will provide insufficient penalty
for this (with the penalty arising solely from the γ weighing). On the other hand, as a
result of the inhibitor penalty in (10), the algorithm may continue to reduce the dosing
even further rather than increasing it to escape this suboptimal policy. The result is that
the targeted cell population proliferates at maximal capacity while dosing fluctuates around
the minimal value of zero drug administration. This zero-dosage convergence problem was
successfully resolved by assigning a significanty lower (20-fold) weight to the mid-episode
dosage penalty if the total cell population exceeded the initial cell population by more than
1 cell for every initially present 104 cells. The incorporation of the binary penalty function
led to significantly improved stability and reduced sensitivity to the exact choice of wα.
4 Training and results
Up to four cell types with different dose responses were permitted to occur in each train-
ing scenario, with the most susceptible type initially dominating the population but with
different cell populations allowed to emerge as early as the first time step. For single-drug
training the dose responses shown in Fig. 2 were assumed. For combination therapy (two-
drug) training, one drug was defined as the “first-line” drug and the second as the “last-line”
drug via respective choices of wα. The responses of the black and blue phenotypes to both
the first-line and last-line drugs were taken to be identical to those shown in Fig. 2. The
more resistant phenotypes (red and green) were assumed to be completely resistant to the
first-line drug (by assigning them a very large value of ρ) and to have the dose response
shown in Fig. 2 to the last-resort drug.
In the single-drug case, in the early stages of training the dosages were increased rapidly
and uniformly in all time steps; at that point the dosages were too high for any failures
to occur. After about 180 episodes considerable decreases in dosing began to occur (also
uniformly). The rate of decrease slowed down once the dosage reached the approximate
level necessary to eliminate the most resistant cell subpopulations (at about 500 epidoes),
with dosing still uniform over the entire course of treatment. At that point increasing
specialization in dosage at different time intervals in response to different mutations began
to occur, and the baseline (no-mutation) dosing continued to further decrease in decision
time steps following the first time step. Dosing during the first time step remained high even
as subsequent doses were brought substantially lower. For these doses training gradually
alternated for a long time between a gradual monotonic decrease, uniform dosing, and a
gradual monotonic increase, eventually establishing the monotonic increase characteristic of
the baseline dosing observed after training converged (top row of Fig. 4). Dosing during the
first time step was eventually brought further down. In the early stage of training episode
failures would occasionally occur; this ceased to happen later in training, at which point
further improvements in learning were on dosing optimization.
In dual-drug training, similar uniform increases were observed in early training for both
drugs, with the first-line drug (lower penalty) initially increasing more, but with this increase
reversed after about 100 episodes (recall that lower dosages of the first-line drug are needed
to suppress the mutations that are not completely resistant to it). By ∼ 220 episodes into
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Figure 3: MSE loss during training for the training with one drug and two drugs. Training was
generally smoother and the MSE loss flattened somewhat earlier in the one-drug case. A low-pass
filter was applied to obtain the black curves. Mutation parameters for the training shown were
Pepis,mut = 0.3, Pepis,mut = 0.03, ζ = 5× 10−6, and w1 = 16, w2 = 3w1 for the first-line and last-line
drugs respectively.
training the first-line drug was not administered at all - but treatments were still successful
since the last-line drug is capable of suppressing all cell types, albeit at a higher penalty.
The last-line dosage continued to be uniformly decreased until treatment failures started
occurring and was subsequently increased to the level at which it could suppress mutant
populations without specialization. Decreases again began occurring at that point, and the
policy also started applying the first-line drug again. Training from that point on involved
specialization in response to mutation and experimentation with various amounts of the
first-line and last-line drugs.
Training was stopped after no further reduction was observed in the MSE loss and the
actor policy loss had stabilized. The MSE loss flattened at ∼ O (10−3) − O (10−2), and
this was observed to occur in single-drug training after a somewhat smaller number of
training episodes than in dual-drug training for the same parameters (Fig. 3). The policy
parameters were saved every 100 episodes for later reference and the resulting policies were
analyzed after training. Following training convergence (determined as described above)
dosing was generally similar for policy parameters recorded at different episodes, with some
minor fluctuations observed. In the dual-drug case, when no mutations were experienced,
the learned policies either administered no last-line drug at all or negligibly small amounts
of it only in the first and last time step (Fig 5).
Responsive adaptation to random events and system perturbations
A hallmark of both the single-drug and combination therapy policies is the responsive
adaptation to random population composition changes (Fig. 4 and Fig. 5) insofar as both
the appearance of a new cell type and stochastic fluctuations of already-present cell types.
On a test set of 1000 episodes simulated randomly with training parameters a 100% success
rate was obtained in both the single-drug and dual-drug cases (all episodes recorded involved
the occurrence of mutations). Multiple concurrent subpopulations are handled well by the
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policies learned. In single-drug therapy, higher drug pulses are only administered after
observing an emergent resistant subpopulation, and baseline dosing is restored following the
elimination of this subpopulation (Fig 4). The dosage administered in these pulses directly
increases with the resistance and population of the observed cell type. In combination
therapy (Fig 5), the policy switches to the last-line drug when the red and green phenotypes
are observed and switches back to the first-line drug after these cells are eliminated. For
the low-resistance blue phenotype appropriate dosing increases are done exclusively with
the first-line drug.
This is particularly remarkable given that the black and blue phenotypes are susceptible
to the same extent to both the first- and last-line drugs. The sharp difference in drug admin-
istration is thus attributable to the differing incentives supplied in the reward assignment
(w2 = 3w1).
Robustness to changes in mutation parameters
In a given episode, the rate of resistant subpopulation emergence and the extent of it
were controlled by Pstep,mut and ζ, respectively. To assess the robustness of the policy to
variations in these parameters the success rates of policies shown in Fig. 4 (one drug) and
Fig. 5 (two drugs) were tested over parameter combinations (100 trials for each combination)
that significantly exceeded the training parameters. No deterioration in performance was
found for parameter combinations within and substantially above the expected biological
values: 100% success was recorded for testing of up to a 10-fold increase in Pstep,mut and more
than a 1000-fold increase in ζ, which controls the number of resistant mutants observed.
No failures were recorded for ζ of up to 1% of the expected increase in susceptible cells in
any time interval (recall that the actual number of cells is randomly generated according
to Eq. 3 with respect to ζ). Slight performance deterioration was found at the very high
end of the ζ range tested (ζ = 5%), but success rates of ≥ 99% were still recorded for these
parameter combinations4; we note that this high end of the range is in significant excess of
resistant cell proportions that may be naturally expected [8].
Generally, the robustness of the learned policies to such strong parameter deviations
implies that it may be possible to apply them to cases where the detection threshold for
newly emergent populations is higher due to lower-resolution diagnostics. However, modifi-
cations accounting for the resolution at subsequent time steps will likely be needed in such
cases.
Policy behavior in the administration of baseline dosing
Typical single-drug baseline (no-mutation episode) dosing exhibits slightly elevated dosages
at the start of each episode that then mildly drop. Subsequent decision time steps involve
approximately-constant but mildly monotonically increasing dosages. An episode can ter-
minate at various points in time even in the absence of mutations (top rows of Figs. 4 and 5)
due to variations in the initial cell population size of up to an order of magnitude as well
4Tests were performed with the policy parameters obtained after 95,000 episodes of training for both the
single-drug and dual drug policies, shown in Fig. 3.
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as demographic fluctuations at low populations toward the end of treatment. The dosing is
seen to adjust in accordance with these variations.
We can gain insight into the reason for this mild monotonic increase by comparing the
single-drug dosing with the dual-drug dosing policies, where we can isolate the effects of two
of the mutations due to the differing responses to the two drugs. In the combination therapy
case, after the first time step the first-line drug is administered at a nearly-constant value
with no increase in dosing as the treatment proceeds. On the other hand, as noted above,
occasional minor last-line drug dosages at the very beginning and end of non-mutation
episodes can be observed in some runs5. One explanation for these dosages is that they
may arise from learning that if resistant phenotypes emerge at the beginning or the very
end of treatment then an immediate response via last-line dosing is paramount to achieving
an optimal treatment not involving higher-than-necessary dosing. In the single-drug case
a dosage increase can combat these mutations, and the observed monotonic rise may thus
emerge from the policy’s anticipation of more resistant phenotypes. It is therefore appears
plausible that the anticipation of late-stage higher-resistance mutations drives this increase
rather than any aspects of the susceptible cell population growth.
Learned preference for short treatment times
All explicit optimization incentives that were given involved the dosage administered rather
than the time of treatment (Section 3.2). As previously explained, the main challenge in
the dosing problem is the balancing of the higher dosages needed to suppress resistant cell
populations with the need to keep toxicity low. Rewards in the setup implemented here
purposely did not incorporate any direct incentives for shorter treatment times, focusing
instead on dosage minimization. Although conservative dosing was a strong feature of all
learned policies, the policies learned in training involved a strong preference for shorter
treatment times even at the expense of higher dosing, typically eliminating the cell popu-
lation well in advance of the maximal treatment time. This is particularly evident from a
comparison of the policy response in its dosing vs. its treatment time (Figs. 6a and 6b) to
increases in the mutation rate per step (Pstep,mut) and resistant cell supply via ζ (Eq. 3):
the policy compensates for the increased resistance almost exclusively through dosage in-
creases, while treatment time is kept nearly constant. This behavior may arise through
a combination of learned preferences based on dosing penalties and mutation parameters,
and in training for a real clinical scenario a “clinician-in-the-loop” approach would permit
informed choices in this regard.
5 Discussion
This paper presented a method for single-drug and combination therapy feedback control
that results in policies capable of responsive and robust adaptation to changes in a stochastic
dynamical system of evolving cell populations. Model-free deep reinforcement learning was
supplemented with model information on system trajectory estimation into feature engi-
neering and reward assignment, which was found to significantly improve learning. Various
5At the beginning of the treatment this was only observed to coincide with a slight dip in the first-line
dosage.
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Figure 6: Policy preference for early termination times can be seen by analyzing the single-drug
dosing behavior (Fig. 4) at different (Pstep,mut, ζ) parameter combinations for episodes in which
mutations occurred. (a): when ζ is increased in testing over the training value (red dot), the mean
total dosage in an episode (purple) increases significantly, but the time of the episode (orange)
remains near-constant, exhibiting a strong policy preference for maintaining short treatment times
at the cost of higher baseline dosage. (b): a preference for dosage rather than time increases is also
observed for increases in Pstep,mut.
aspects of the resulting policies were investigated in this study and may help guide future
efforts training similar systems in which some trajectory estimation is possible, the proba-
bility of random perturbing events may not be known, and a tradeoff between conflicting
target goals (here: low toxicity with the need to properly target resistant cell populations)
exists.
Given the demonstrated ability of the policies that were learned in robustly adjusting
to large variations in certain parameters on which they were not trained, an interesting
question for future exploration is how accurately the underlying structure of the model –
here logistic growth dynamics – needs to be known for policy training. Higher flexibility
in this regard would enable controller development with more limited predictive knowledge
of the dynamics. The resolution of feedback observations and especially their frequency is
likely to play an important role in this flexibility. Here, observations were assumed to be
generated at discrete time points but be reflective of the population composition at these
time points. Practical implementation would likely necessitate accounting for a certain time
delay in obtaining such observations, and future directions for the development of CelluDose
include the incorporation of delayed feedback and lower-resolution observations that lead
to partial observability of the system.
As higher-resolution diagnostics, more sophisticated modeling techniques, and a recog-
nition of the need for patient-specific care are making increasing gains in healthcare, the
need for appropriate therapeutic control methods is likely to rise. The ultimate goal in pre-
cision dosing – a feedback loop in which drug absorption and response are tightly monitored
and used to determine subsequent dosing – remains for now an elusive goal in all but a few
cases [57]. The method presented here is intended for eventual use in this context under
consistent monitoring of the targeted cell population composition in terms of the variability
in its dose responses.
An important advantage of modeling and simulation in developing drug dosage con-
trollers is the ability to investigate a large range of drug schedules even prior to clinical
20
trials and to thus potentially inform the development of clinical trials. The focus of the
implementation presented here is on the drug responses and trajectories of an evolving
population of cells. For clinical applications, modeling would need to additionally include
patient-relevant models of drug absorption and immune system response. With appropriate
diagnostics, the setup described here could be implemented for the automated control of
laboratory bacterial evolution experiments and establish the roles and interplay of decision
time intervals, diagnostic resolution, and model uncertainty as part of the controller design.
This would be a crucial step toward future clinical application and a validation of the utility
of artificial intelligence-driven approaches in simulation-based biomedical controller design.
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A Master equation to stochastic differential equations
A.1 Master equation for the population dynamics of d phenotypes
Let Ai denote a single cell of phenotype i. We consider d phenotype with equal resource
utilization evolving subject to a resource capacity given by K. Following a simplified setup
of [58], we initially consider a spatial grid permitting up to one individual of type Ai per
site. If empty, individual in site is denoted by E. The rates of birth and death of cells of
type i are denoted by β˜i and δ˜i respectively:
Birth: AiE
β˜i→ AiAi
Death: Ai
δ˜i→ E
At each time step we sample the population. On a fraction η of these events we randomly
choose two individuals and allow them to interact, but since we do not consider direct
competition effects other than through shared limited resources, we ignore combinations
in which both Ai cells were picked and therefore restrict to picking only the combination
Ai and E. In a fraction 1 − η of these events we choose only one individual randomly (if
only E’s are drawn, the drawing is done again). The probabilities of picking the different
combinations are given by
P (AiE) : 2η
ni
K
(
K −∑k nk
K − 1
)
P (Ai) : (1− η) ni
K
where ni is the population of phenotype i. We will denote the transition probabilities from
state n = (n1, ..., nd) to state n
′ by T (n′|n). They are thus given byT (n1, ..., ni + 1, ..., nd|n) = 2ηβ˜i niK
(
K−∑k nk
K−1
)
≈ 2ηβ˜i ni(K−
∑
k nk)
K2
T (n1, ..., ni − 1, ..., nd|n) = (1− η)δ˜i niK
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where for simplicity we replace K − 1→ K as we will be considering the large-K limit for
the subsequent diffusion approximation. The master equation is given by
dP (n, t)
dt
=
∑
d
i=1 {T (n|n1, ..., ni + 1, .., nd)P (n1, ..., ni + 1, .., nd, t)
+ T (n|n1, ..., ni − 1, .., nd)P (n1, ..., ni − 1, .., nd, t)
− [T (n1, ..., ni − 1, .., nd|n) + T (n1, ..., ni + 1, .., nd|n)]P (n, t)}
(11)
subject to the initial condition P (n, 0) = δn0,n (Kronecker delta, not to be confused with
the death rates δi). We must also impose boundary conditions,{
T (n1, ..., ni = 0, ..., nd|n1, ..., ni = −1, ..., nd) = 0
T (
∑
i ni = K|
∑
i ni = K + 1) = 0.
A.2 Diffusion approximation: the Fokker-Planck equation and Ito stochas-
tic differential equations
By assuming that the resource capacity K is large compared to the population levels ni,
we can approximate ϕi = ni/K  1 as continuous variables; we denote P (n1, ..., ni ±
1, ..., nd, t) ≡ Pϕ(ϕi ± 1) and define{
f (ϕi) ≡ δiϕi
g (ϕi) ≡ βiϕi
(
1−∑dj ϕj)
where we have rescaled the death and birth rates as δi ≡ (1− η) δ˜i and βi ≡ ηβ˜i. Eqn. (11)
can then be rewritten as
dPϕ(ϕ˜, t)
dt
=
d∑
i=1
{[
f
(
ϕi +
1
K
)
Pϕ
(
ϕ1, ..., ϕi +
1
K
, ..., ϕd, t
)
− f (ϕi)Pϕ(~ϕ, t)
]
+
[
g
(
ϕi − 1
K
)
Pϕ
(
ϕ1, ..., ϕi − 1
K
, ..., ϕd, t
)
− g (ϕi)Pϕ(~ϕ, t)
]}
Taylor expanding around ϕi to second order [51] we have that
h
(
ϕi ± 1
K
)
Pϕ
(
ϕ1, ..., ϕi ± 1
K
, ..., ϕd, t
)
= h (ϕi)Pϕ(~ϕ, t)± 1
K
∂ (hP )
∂ϕi
∣∣∣∣
~ϕ
+
1
2K2
∑
j
∂2 (hP )
∂ϕ2j
∣∣∣∣∣
~ϕ
,
which yields, after rescaling time as τ = t/K, the Fokker-Planck equation
∂Pϕ(~ϕ, t)
∂τ
=
d∑
i=1
 ∂ ((f − g)P )
∂ϕi
∣∣∣∣
~ϕ
+
1
2K
∑
j
∂2 ((f + g)P )
∂ϕ2j
∣∣∣∣∣
~ϕ
 ,
which corresponds to the system of Ito stochastic differential equations
dϕi = − (f (ϕi)− g (ϕi)) dt+ 1√
K
∑
m
δmi
√
f (ϕm) + g (ϕm)dWm(t)
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where the white noise Wk(t) satisfies{
〈Wk(t)〉 = 0
〈Wk(t)W`(t′)〉 = δk`δ(t− t′)
(12)
and δmi is the Kronecker delta (not to be confused with the death rate δi). We have that
f (ϕi)± g (ϕi) =
1− d∑
j
ϕj
[δi ϕi
1−∑dj ϕj − δiϕi + δiϕi ± βiϕi
]
= ϕi
1− d∑
j
ϕj
[δi( ∑dj ϕj
1−∑dj ϕj
)
+ δi ± βi
]
.
If we redfine xi ≡ Kϕi as the levels (concentrations) rather than proportions of the popu-
lations, we observe that the fraction∑d
j ϕj
1−∑dj ϕj =
1
K
∑d
j xj
1− 1K
∑d
j xj
approaches 1 in the large-K limit, in which case we have
f (ϕi)± g (ϕi)→ 1
K
(δi ± βi)xi
(
1−
∑d
j xj
K
)
yielding the system (2)
dxi(t)
dt
= (βi − δi)xi(t)
(
1−
∑d
j=1 xj(t)
K
)
+
√√√√(βi + δi)xi(t)(1− ∑dj=1 xj(t)
K
)
Wi(t)
for i = 1, .., d. To prevent the term in the square root of the noise from occasionally briefly
dipping below zero and resulting in imaginary numbers (due to the cell subpopulations
potentially dipping below zero during a simulation step before being set to zero), this term
is clipped at zero.
B Neural network architecture and hyperparamer choices
The actor and critic network (and respective target network) architecture used is the same
as in the original DDPG paper [24], with the notable difference that significant performance
improvement was obtained with the addition of an extra hidden layer (45 units) in the actor
network6 and that narrower hidden layers (60 and 45 units respectively) were implemented
to avoid overfitting. All hidden layers employed rectified linear activation functions; the
output layer of the actor was set to a hard tanh with range between 0 and a chosen maximum
dose in order to allow for the dosage to drop to exactly zero (particularly important when
6Notably, the addition of an extra layer in the critic network led to degraded performance.
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multiple drugs are considered). Weights were initialized randomly but biases were set to a
positive value informed by the evolution of the deterministic part of (2) (see Appendix C
for a detailed description). This was found to prevent convergence to a suboptimal policy
in which the minimal control (0) was applied at every time step early in the training.
No batch normalization was used at hidden layers, but features were rescaled prior to
being added to the replay buffer in the following manner. Cell concentrations xi were
rescaled as
xi → log (xi + 1)
log(K)
.
Since cell concentrations can vary by multiple orders of magnitude, this was found to be
necessary for smooth convergence. The growth rate gall was rescaled as
gall → gall − gmin
gmax − gmin
where gmax was defined in (9) and gmin was set to the negative of the death rate, −δ, which
is the lowest growth rate (δ is the highest rate of decline) possible in the system.
Adam optimization was used with learning rates of 10−5 for the actor network and
10−4 for the critic network as learning was found to be unstable for higher rates. Training
was done with mini-batch size of 128 and a replay buffer of size 106. Soft updates to the
target networks were done with τ = 0.001 and the RL discount factor was set at γ = 0.99.
Exploration was done with an Ornstein-Uhlenbeck process with θ = 0.15, σ = 0.3, and
δt = 10−2. Parameters used in the reward choice that resulted in successful training were
cend,success = 40, w1 = w2 = 1 , c1 = 2, cend,fail = 20, cΦ = 10. Single-drug training
was done with both η1 = 16 and η1 = 4. Combination therapy (two drugs) training was
done with η2 = 3 × η1 under the assumption that the drug able to effectively target the
higher-resistance cells is a last-resort drug that also involves higher toxicity.
C Bias initialization
If we assume the lowest-variance policy – constant uniform dosing – and permit no mutations
to occur, then in deterministic evolution the number of baseline-phenotype cells under
constant dose I starting from a population x0 will be given at time t by the solution of the
noise-free d = 1 system equivalent of (2):
x(t) =
x0e
g(I)t
1 + x0K
[
eg(I)t − 1] . (13)
where g(I) = β
1+ I
ρ
− δ. If the population must be reduced to xmin (here, < 1 cell) within a
time Tmax, then the dosage must be no less than
Imin = ρ
 βTmax
δTmax − log
(
x0(K−xmin)
xmin(K−x0)
)

for treatment to be successful. Initial cell populations were allowed to vary by up to an order
of magnitude; by taking the maximum value allowed in this range we compute Imin and set
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the bias to five times this value or to 75% of the maximal inhibit - whichever is smallest
(typically 5Imin). xmin was set to just under 1 cell (0.98) as the population falling below
a single cell marked the conclusion of a successful episode. The full initialization for both
actor and critic networks were saved and used in subsequent runs for training consistency.
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